SCHEMBL3451285

SCHEMBL3451285

COC(=O)c1cc(-c2cnc(Nc3ccc(F)c(Cl)c3)nc2-n2nc(C(F)(F)F)cc2C)cnc1OC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.37
TYRO3 Q06418 1/20 0.37
MERTK Q12866 1/20 0.37
RIPK1 Q13546 3/20 0.36
PTK2 Q05397 1/20 0.36
EGFR P00533 2/20 0.36
CSNK2A1 P68400 1/20 0.36
APP P05067 1/20 0.35
STK17A Q9UEE5 2/20 0.35
KCNN3 Q9UGI6 1/20 0.35
CSF1R P07333 1/20 0.35
ULK1 O75385 1/20 0.35
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
STK17B O94768 1/20 0.35
STIM1 Q13586 1/20 0.35
ORAI1 Q96D31 1/20 0.35
ABL1 P00519 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3449007 0.94 EGFR (0.41) AXLTYRO3MERTKRIPK1PTK2
SCHEMBL3451615 0.93 CSF1R (0.41) AXLTYRO3MERTKRIPK1PTK2
SCHEMBL13312703 0.93 SCN9A (0.37) AXLTYRO3MERTKRIPK1PTK2
SCHEMBL3448216 0.93 PTK2 (0.42) RIPK1PTK2ULK1
SCHEMBL3379025 0.92 SYK (0.38) AXLMERTKEGFRCSNK2A1STK17A
SCHEMBL3451382 0.92 RIPK1 (0.38) RIPK1PTK2EGFRSTK17ACSF1R
SCHEMBL3447752 0.91 CNR2 (0.43) TYRO3MERTKSYK
SCHEMBL3449975 0.90 SCN9A (0.46)
SCHEMBL3449227 0.89 SCN9A (0.42) RIPK1EGFRPIK3CDPIK3CAPIK3CB
SCHEMBL3373115 0.89 SYK (0.39) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD AXL 2812/4885TYRO3 2798/4885MERTK 1743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.